𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma

✍ Scribed by Mark M. Zalupski; Philip A. Philip; Patricia LoRusso; Anthony F. Shields

Publisher
Springer
Year
1997
Tongue
English
Weight
101 KB
Volume
40
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of spirogermanium in pati
Phase II study of spirogermanium in patients with advanced colorectal carcinoma
✍ Jaffer A. Ajani; Jack S. Faintuch; Roxann K. McClure; Bernard Levin; Bruce M. Bo πŸ“‚ Article πŸ“… 1986 πŸ› Springer US 🌐 English βš– 193 KB

Twenty one evaluable patients with advanced colorectal carcinoma were treated with continuous infusion of spirogermanium at a median daily dose of 150 mg/rn 2 (range 120-210) for five consecutive days every 14 days. Treatments were accomplished by using outpatient infusion devices. Fifteen patients

Phase II study of daunorubicin in previo
Phase II study of daunorubicin in previously untreated patients with advanced colorectal carcinoma
✍ Harvey, J. ;Bonnem, E. ;Grady, K. ;Goodman, A. ;Schein, P. πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 111 KB

Fourteen patients with advanced measurable colorectal cancer were treated with daunorubicin hydrochloride (DNR). The drug was administered at a dose of 15 mg/m2 on day 1 through 3 and 8 through 10. After a Cday rest period DNR was given in weekly injections of 15 mg/m2. There were no partial or comp